Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Oct 14, 2011


Vermillion announced this week that Sandra Gardiner has resigned as vice president and chief financial officer and is leaving the company to take a job with an undisclosed firm in the San Francisco Bay Area.

The company also appointed Eric Schoen as chief accounting officer. Previously Schoen was corporate controller at Vermillion. Before that he was revenue controller for Borland Software.

Hybrigenics has appointed Alain Munoz to its board of directors. Munoz replaces Bernhard Ehmer, president of ImClone Systems, and will chair the company's clinical advisory board.

Munoz is a board member at several biotech companies including Vivalis, Novagali Pharma, and Zealand Pharma. Previously he was R&D vice president at the Sanofi Group and senior vice president of the pharmaceutical division at Fournier.

Riccardo Pigliucci has joined Bioscale's board of directors.

Pigliucci is the former chief operating operator of PerkinElmer as well as CEO of Life Sciences International and Discovery Partners International. He was also lead director on the board of Dionex, which was recently purchased by Thermo Fisher Scientific.

Protea Biosciences has hired Alessandro Baldi as vice president and general manager.

Previously Baldi was senior director of PerkinElmer's mass spectrometry business.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.